Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14613361 | 0.80 | CYP2D6 (0.39) | SLC18A3OPRM1OPRK1OPRL1MEN1 | |
| SCHEMBL14197777 | 0.79 | OPRM1 (0.39) | SLC18A3OPRM1OPRK1OPRL1MEN1 | |
| SCHEMBL2116898 | 0.77 | PKM (0.42) | PKMSLC18A3OPRM1OPRK1OPRL1 | |
| SCHEMBL2116900 | 0.75 | PKM (0.50) | PKMSLC18A3OPRM1OPRK1OPRL1 | |
| SCHEMBL2114638 | 0.71 | PKM (0.45) | PKMSLC18A3OPRM1OPRK1OPRL1 | |
| SCHEMBL27695030 | 0.71 | PKM (0.41) | PKMSLC18A3OPRM1OPRK1OPRL1 | |
| SCHEMBL28100676 | 0.70 | PKM (0.59) | PKMSLC18A3OPRM1OPRK1OPRL1 | |
| SCHEMBL2114640 | 0.70 | PKM (0.53) | PKMSLC18A3MEN1KMT2AALDH1A1 | |
| SCHEMBL2114628 | 0.68 | OPRM1 (0.46) | PKMSLC18A3OPRM1OPRK1OPRL1 | |
| SCHEMBL803892 | 0.67 | KDM4E (0.44) | SLC18A3OPRM1OPRK1OPRL1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | PKM 2745/4885SLC18A3 3683/4885OPRM1 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.